Geneva, Nov. 2 -- International Clinical Trials Registry received information related to the study (NCT07882173) titled 'Epcoritamab as Consolidative Therapy for Waldenstr(SqrRoot)(Delta)m Macroglobulinemia (WM) Treated With a Bruton Tyrosine Kinase Inhibitor (BTKi)' on Oct. 19.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Condition:
Waldenstrom Macroglobulinemia
Intervention:
Drug: epcoritamab
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: October 28, 2026
Target Sample Size: 24
Countries of Recruitment:
United Sta...